Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceSin categoríaVideos

EMA recommends a new indication for daratumumab in adult patients with newly diagnosed myeloma who are eligible for autologous stem cell transplant

On 19 September the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a new indication for daratumumab (Darzalex®, commercialised by Janssen). The new indication is a combination of daratumumab, bortezomib, lenalidomide and dexamethasone and it brings a significant benefit with respect to progression-free survival compared to…

Read more

Living with myeloma finding my way to greater well-being

Every myeloma patient has a story to tell. And every story captures a very personal experience of our incurable blood cancer. Living with myeloma is more than navigating the physical challenges of illness and treatment. It is also about finding a path through mental health issues: toxic thoughts, rollercoaster emotions and imperilled well-being. Because myeloma…

Read more

The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and Wales

  On the 21st of June NICE, the United Kingdom’s public body for medicine appraisals, approved the use of the UK’s first bispecific drug for myeloma, elranatamab. Evidence from an ongoing clinical trial showed that the drug can increase the length of time people are in remission. Based on this evidence, elranatamab, commercially known as…

Read more

European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myeloma

The European Commission has approved marketing authorisation extension for the CAR-T treatment ciltacabtagene autoleucel (Carvytki®), also known as cilta-cel, for use in patients who have received at least one prior therapy, including an immunomodulatory agent (IMiD – such as lenalidomide and pomalidomide) and a proteasome inhibitor (PI – such as bortezomib or carfilzomib), have demonstrated disease progression…

Read more

MPE launches the Myeloma and AL Amyloidosis European Clinical Trial Navigator

Brussels, 23 April 2024 – Myeloma Patients Europe (MPE) has launched today the English version of the Myeloma and AL Amyloidosis European Clinical Trial Navigator, an online search tool to learn about and find clinical trials for myeloma, monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma (SMM) and AL amyloidosis in Europe. With this tool, MPE wants to facilitate the search…

Read more
June

July 2026

August
MO
TU
WE
TH
FR
SA
SU
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
Events for 1st July
No Events
Events for 2nd July
No Events
Events for 3rd July
No Events
Events for 4th July
No Events
Events for 5th July
No Events
Events for 6th July
No Events
Events for 7th July
No Events
Events for 8th July
No Events
Events for 9th July
No Events
Events for 10th July
No Events
Events for 11th July
No Events
Events for 12th July
No Events
Events for 13th July
No Events
Events for 14th July
No Events
Events for 15th July
No Events
Events for 16th July
No Events
Events for 17th July
No Events
Events for 18th July
No Events
Events for 19th July
No Events
Events for 20th July
No Events
Events for 21st July
No Events
Events for 22nd July
No Events
Events for 23rd July
No Events
Events for 24th July
No Events
Events for 25th July
No Events
Events for 26th July
No Events
Events for 27th July
No Events
Events for 28th July
No Events
Events for 29th July
No Events
Events for 30th July
No Events
Events for 31st July
No Events